Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial ...

A set of vertices S of a connected graph G is a nonseparating independent set if S is independent and G–S is connected. The nsis number 𝒵(G) is the maximum cardinality of a nonseparating independent ...

Discover how to effortlessly create stunning, interactive charts with Syncfusion in .NET MAUI. Enhance your mobile and desktop applications with powerful data visualization features using this ...

npm i https://github.com/jodymgustafson/math-graph-canvas/releases/download/v1.1.0/math-graph-canvas-1.1.0.tgz Use the CartesianGraph class to create a cartesian ...

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...

Cartesian is among the leaders in a push by drugmakers to develop cell therapies for autoimmune conditions. Like Kyverna Therapeutics, Cabaletta Bio and many others, the company aims to show that a ...